stockrowExelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) Return on invested capital
Exelixis, Inc.'s return on invested capital over the twelve months to 30 September 2026 was 66.6%, up 17.1 percentage points from fiscal 2025 (49.5%). Over the past ten years it has ranged from −68.9% (fiscal 2015) to 49.5% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 49.5% | 16.11 |
| FY2024 | 33.4% | 24.93 |
| FY2023 | 8.42% | (2.25) |
| FY2022 | 10.7% | (13.43) |
| FY2021 | 24.1% | 13.87 |
| FY2020 | 10.2% | (17.47) |
| FY2019 | 27.7% | (18.47) |
| FY2018 | 46.2% | 46.17 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 68.94 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| EXEL Exelixis, Inc. | 66.6% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 59.4% |
| HALO Halozyme Therapeutics, Inc. compare | 19.9% |
| ASND Ascendis Pharma A/S compare | 15.1% |
| JAZZ Jazz Pharmaceuticals PLC compare | 3.86% |
| BBIO BridgeBio Pharma, Inc. compare | 0.00% |
| SMMT Summit Therapeutics PLC compare | 0.00% |
| BNTX BioNTech SE Sponsored ADR compare | −34.3% |
| INSM Insmed, Inc. compare | −247.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on EXEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement